Daily Sepsis Research Analysis
Analyzed 30 papers and selected 3 impactful papers.
Summary
The most impactful papers address early sepsis-associated coagulopathy detection, mechanistic drivers of sepsis-associated acute kidney injury, and the safety of hydrocortisone in patients with chronic kidney disease and septic shock. Together, they combine large-scale clinical validation, mechanistic experimentation, and clinically important negative observational evidence.
Research Themes
- Simplification and validation of sepsis-associated coagulopathy criteria
- LCN2-mediated ferroptosis in sepsis-associated acute kidney injury
- Real-world safety of hydrocortisone in septic shock with chronic kidney disease
Selected Articles
1. Proposal of simplified sepsis-induced coagulopathy criteria (SIC-2) for the detection of early-phase disseminated intravascular coagulation in sepsis.
This retrospective non-inferiority study compared the original SIC definition with a simplified coagulation-centered SIC-2 score in 18,086 patients from MIMIC-IV. SIC-2 showed comparable discrimination for overt DIC within 5 ICU days (AUC 0.854 versus 0.850), while the small reduction in 28-day mortality discrimination was unlikely to compromise its primary coagulation-focused purpose.
Impact: The study addresses a fundamental conceptual problem in sepsis scoring: a coagulation phenotype may be confounded by downstream organ dysfunction. A simpler score could improve interpretability, facilitate bedside screening, and support more biologically focused research on sepsis-associated coagulopathy.
Clinical Implications: SIC-2 may be considered as a coagulation-centered screening phenotype for early sepsis-associated coagulopathy and DIC risk. Before routine guideline adoption, prospective external validation and assessment of its effect on anticoagulant or blood-product decisions are needed.
Key Findings
- The study included 18,086 patients with sepsis from the MIMIC-IV database.
- SIC-2 had similar discrimination for overt DIC within 5 ICU days compared with SIC: AUC 0.854 versus 0.850.
- Removing SOFA caused only a small reduction in 28-day mortality discrimination: AUC 0.614 versus 0.621, with an absolute difference of 0.007.
Methodological Strengths
- Large critical-care cohort with a prespecified non-inferiority comparison.
- Evaluation included discrimination, calibration, mortality, and organ-support-free outcomes.
Limitations
- The retrospective analysis of a single database may limit generalizability across healthcare systems and populations.
- The study assessed prediction rather than whether SIC-2-guided management improves patient outcomes.
Future Directions: Prospective multicenter validation should examine calibration across diverse populations and determine whether SIC-2 can improve early DIC recognition, guide coagulation-directed treatment, and reduce inappropriate use of severity-driven interventions.
BACKGROUND: Sepsis-induced coagulopathy (SIC) was introduced to identify early coagulation abnormalities in sepsis and to predict progression to overt disseminated intravascular coagulation (DIC). However, inclusion of the SOFA may conflate coagulation-specific biology with overall illness severity. OBJECTIVES: To evaluate whether removal of the SOFA component preserves the diagnostic and prognostic performance of SIC and to determine whether a simplified coagulation-centered construct (SIC-2) maintains clinical utility. METHODS: In a retrospective cohort of 18,086 patients with sepsis from the MIMIC-IV database, we compared original SIC and SIC-2 using a non-inferiority framework.
2. The potential mechanism investigation of Lipocalin-2 in ferroptosis via the AMPK/SIRT3/FOXO3a axis in sepsis-associated acute kidney injury.
Using cecal ligation and puncture mice and LPS-stimulated HK-2 renal tubular cells, the study investigated how LCN2 contributes to renal ferroptosis in sepsis-associated acute kidney injury. LCN2 deficiency reduced renal injury, oxidative stress, inflammation, and ferroptosis, whereas LCN2 overexpression worsened these changes; activation of AMPK or restoration of SIRT3 attenuated the effects.
Impact: The paper provides a coherent mechanistic link between a clinically recognized biomarker, LCN2, and ferroptotic kidney injury through the AMPK/SIRT3/FOXO3a axis. This identifies a potentially actionable pathway for a complication of sepsis with limited targeted therapies.
Clinical Implications: LCN2 and the AMPK/SIRT3/FOXO3a pathway may serve as candidate biomarkers or therapeutic targets for SA-AKI. The findings are preclinical and should not yet guide patient treatment without validation in human tissue, pharmacologic studies, and clinical trials.
Key Findings
- LCN2 knockout attenuated renal pathological injury, oxidative stress, inflammatory cytokines, and ferroptosis in septic mice.
- LCN2 overexpression aggravated LPS-induced ferroptosis and oxidative stress in HK-2 renal tubular epithelial cells.
- AMPK activation or SIRT3 overexpression reversed LCN2-associated ferroptotic and oxidative injury, implicating the AMPK/SIRT3/FOXO3a axis.
Methodological Strengths
- Mechanistic triangulation using both an in vivo murine sepsis model and an in vitro human renal epithelial-cell model.
- Genetic manipulation and pathway-rescue experiments strengthened causal interpretation.
Limitations
- The findings were generated in experimental models and may not reproduce the heterogeneous biology of human SA-AKI.
- The abstract does not provide clinical patient numbers or human validation of LCN2-pathway relationships.
Future Directions: Future studies should validate the pathway in human SA-AKI tissue and longitudinal patient samples, identify pharmacologic modulators with acceptable safety, and test whether pathway-directed treatment improves renal recovery and survival.
Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication of sepsis. Lipocalin-2 (LCN2), a biomarker for SA-AKI, has an undefined role and underlying molecular mechanism in regulating renal ferroptosis. This study aimed to elucidate the regulatory function and potential mechanism of LCN2 in renal ferroptosis during SA-AKI. In vivo, a murine sepsis model was established using cecal ligation and puncture (CLP), while in vitro, human renal tubular epithelial cells (HK-2) were stimulated with lipopolysaccharide (LPS) to mimic SA-AKI. Histopathological, biochemical, and molecular analyses were performed to assess renal injury, oxidative stress, inflammatory responses, and ferroptosis-related indicators.
3. Hydrocortisone Use for Septic Shock in Patients With CKD.
This large retrospective TriNetX cohort evaluated hydrocortisone in nondialysis CKD patients who developed septic shock. After propensity matching of 13,141 patients per group, hydrocortisone exposure was associated with higher 90-day mortality, major adverse kidney events, major cardiovascular or cerebrovascular events, and mechanical ventilation, while reinfections were less frequent.
Impact: The study focuses on a high-risk population often underrepresented in therapeutic evidence and reports clinically important harm signals despite extensive propensity matching. These findings challenge uncritical extrapolation of general septic-shock steroid evidence to patients with CKD.
Clinical Implications: Hydrocortisone should not be assumed to have the same benefit-risk profile in CKD patients as in the general septic-shock population. Clinicians should individualize steroid decisions, monitor renal, cardiovascular, respiratory, and metabolic complications closely, and recognize that causality remains uncertain because this was not a randomized trial.
Key Findings
- The propensity-matched cohort included 13,141 CKD patients treated with hydrocortisone and 13,141 untreated patients.
- Mortality was higher with hydrocortisone: 32.4% versus 27.8%, adjusted HR 1.31, 95% CI 1.25-1.36.
- Hydrocortisone was associated with higher risks of MAKE, MACCE, and mechanical ventilation, but lower reinfection risk.
Methodological Strengths
- Very large national multicenter real-world database with extensive propensity-score matching.
- Assessment included mortality, kidney, cardiovascular, respiratory, infectious, metabolic, and neurologic outcomes.
Limitations
- Residual confounding by indication and illness severity may explain part or all of the observed harm associations.
- Treatment dose, timing, duration, vasopressor exposure, and detailed CKD severity may not be fully captured in the database.
Future Directions: Prospective comparative studies and pragmatic randomized trials should determine whether selected CKD subgroups benefit from hydrocortisone, identify harmful treatment patterns, and clarify the balance between reduced reinfection and increased mortality or organ complications.
INTRODUCTION: Patients with chronic kidney disease (CKD) are at higher risk of septic shock and mortality than the general population. Although hydrocortisone is often used as an adjuvant therapy for septic shock in the general population to improve clinical outcomes, its effectiveness in patients with CKD remains understudied. METHODS: We identified a retrospective cohort of patients within TriNetX US collaborative database diagnosed with nondialysis CKD between November 1, 2010 and October 31, 2025 who also developed septic shock. Outcomes of interest within 90 days included all-cause mortality, major adverse kidney events (MAKE) without persistent kidney dysfunction, major adverse cardiovascular or cerebrovascular events (MACCE), mechanical ventilation, hyperglycemia, reinfections, and delirium. Survival analyses and multivariable Cox proportional hazard models were performed.